Lawyers at international firm Osborne Clarke’s Bristol office have advised shareholders of leading orthopaedic company Corin on the acquisition of a majority stake in the business by global investment firm Permira Funds.
Following five years of outstanding growth, Cirencester-based Corin is one of the fastest-growing firms in its sector. The firm produces innovative replacement hip and knee joints and implants used by surgeons across the world.
Following the deal with Permira, substantial investment is expected to fuel the next stage of the company’s development and build further on its strong track record of double-digit growth.
Chief executive Stefano Alfonsi and the management team will continue to lead the firm and will remain significant investors in the company alongside Permira.
Osborne Clarke’s team, led by corporate partner Alisdair Livingstone, advised Corin’s shareholders on the transaction. Among Corin’s shareholders selling to Permira were DeA Capital Alternative Funds SGR (controlled by DeA Capital Group), Hunt Capital and IP (Investimenti e Partecipazioni).
Alisdair was assisted by associate director Chris Yeo, senior associate James Taylor and associate Isaac Paine (corporate), legal director David Nisbet (tax) and associate Alistair Godwin (tax) with support from healthcare specialist Bleddyn Rees (Osborne Clarke consultant).
Rothschild acted as financial advisers to Corin while the Permira funds were advised by financial advisers Vitale & Co and law firm Latham & Watkins.
